Global Sickle Cell Anemia Therapeutics Industry Analysis 2019 - Market Developments and Financials of Key Players - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global Sickle Cell Anemia Therapeutics Market Analysis 2019" report has been added to ResearchAndMarkets.com's offering.

The Global Sickle Cell Anemia Therapeutics market is expected to reach $5,567.75 million by 2026 growing at a CAGR of 12.5% during the forecast period. Sickle-cell anaemia is a disease which is categorized by the existence of sickle-shaped erythrocytes. Sickle-cell anaemia is an inherited, lifelong blood disorder that impacts haemoglobin causing serious damage to the body.

Some of the key factors driving the growth of sickle-cell anaemia therapeutics market are the unmet medical needs and the increase in sickle-cell diseases. However, the side effects associated with current therapies and low awareness among individuals will surely impede the growth of this market.

Based on the Product Type, the pharmacotherapy segment is estimated to have a lucrative growth due to the potential launch of promising pipeline candidates such as Voxelotor, Crizanlizumab, Rivipansel, and Altemia. It is also estimated to lead the market, owing to a strong pipeline and several promising drug launches throughout the forecast period.

The key vendors mentioned are Addmedica, Baxter, Bioverativ, Bluebird Bio, Bristol-Myers, Squibb, Daiichi Sankyo, Eli Lilly, Emmaus Medical, Gamida Cell, Gilead Sciences, Global Blood Therapeutics, GlycoMimetics, HemaQuest Pharmaceuticals, Imara, Ironwood Pharmaceuticals, Johnson & Johnson, Mast Therapeutics, Merck Sharp & Dohme, Micelle BioPharma, and Modus Therapeutics.

Key Questions Answered in this Report:

• How this market evolved since the year 2016
• Market size estimations, forecasts and CAGR for all the segments presented in the scope
• Key Market Developments and financials of the key players
• Opportunity Analysis for the new entrants
• SWOT Analysis of the key players
• Fastest growing markets analyzed during the forecast period
  

Key Topics Covered:

1 Market Synopsis

2 Research Outline

3 Market Dynamics

3.1 Drivers

3.2 Restraints

4 Market Environment

4.1 Bargaining power of suppliers

4.2 Bargaining power of buyers

4.3 Threat of substitutes

4.4 Threat of new entrants

4.5 Competitive rivalry

5 Global Sickle Cell Anemia Therapeutics Market, By Medication

5.1 Introduction

5.2 Antibiotics

5.3 Hydroxyurea

5.4 Pain-Relieving Medications

5.5 Folic Acids

5.6 Antimetabolites

5.7 Vaccines

5.8 Analgesics

5.9 Other Medications

6 Global Sickle Cell Anemia Therapeutics Market, By Therapy

6.1 Introduction

6.2 Hydroxyurea

6.3 L-Glutamine

7 Global Sickle Cell Anemia Therapeutics Market, By Product Type

7.1 Introduction

7.2 Blood Transfusion

7.3 Bone Marrow Transplant

7.4 Gene Therapy

7.5 Pharmacotherapy

8 Global Sickle Cell Anemia Therapeutics Market, By Application

8.1 Introduction

8.2 Adult

8.3 Child

9 Global Sickle Cell Anemia Therapeutics Market, By End User

9.1 Introduction

9.2 Government

9.3 Home Healthcare

9.4 Hospitals

9.5 Infusion Centers

9.6 Private Clinics

9.7 Other End Users

10 Global Sickle Cell Anemia Therapeutics Market, By Geography

10.1 North America

10.2 Europe

10.3 Asia Pacific

10.4 South America

10.5 Middle East & Africa

11 Strategic Benchmarking

12 Vendors Landscape

12.1 Addmedica

12.2 Baxter

12.3 Bioverativ

12.4 Bluebird Bio

12.5 Bristol-Myers Squibb

12.6 Daiichi Sankyo

12.7 Eli Lilly

12.8 Emmaus Medical

12.9 Gamida Cell

12.10 Gilead Sciences

12.11 Global Blood Therapeutics

12.12 GlycoMimetics

12.13 HemaQuest Pharmaceuticals

12.14 Imara

12.15 Ironwood Pharmaceuticals

12.16 Johnson & Johnson

12.17 Mast Therapeutics

12.18 Merck Sharp & Dohme

12.19 Micelle BioPharma

12.20 Modus Therapeutics

For more information about this report visit https://www.researchandmarkets.com/r/kdd40y